Elevation Oncology(ELEV) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Elevation Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Achievements -- Promising initial Phase 1 data of EO-3021 reported in August highlighting 42.8% confirmed ORR observed in Claudin 18.2-enriched subset of gastric and GEJ cancer, with differentiated safety profile -- -- Progressed into dose expansion portion of Phase 1 trial; additional monotherapy data expected in 1H 2025 -- -- Expect to present preclinical data on the combination potential of EO-3021 ...